Search results

Technologies 2

• Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
  eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
• OMNIVAX: Broadly Deployable Infection Vaccine Platform
  OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases.

News 11

View all

• Press Release
  
  A CRISPR fingerprint of pathogenic C. auris fungi
  January 14, 2026
• Press Release
  
  Biomaterial vaccines to make implanted orthopedic devices safer
  November 3, 2025
• Press Release
  
  Using AI, researchers identify a new class of antibiotic candidates
  December 20, 2023

Multimedia 2

• 

  Audio/Podcast
  James Collins: Doing Good Science with an Underdog Spirit – The Pulse Podcast
  James J. Collins is a founding Core Faculty member at the Wyss Institute and the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. Jim serves as a director at the MIT Jameel Clinic, a member of the Harvard-MIT Health Sciences & Technology Faculty, and a member of the Broad...

• 

  Video/Animation
  OMNIVAX: Infection Vaccine Platform
  This video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University.